Difference between revisions of "Synthetic Biology Patent Application Trends 2024"

@@ Line 7: / Line 7: @@
 === Top CPC Codes ===
-* [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media)
+* [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available)
-** Count: 100 patents
+** Count: 102 patents
-** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]]
+** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]]
-* [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media)
+* [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available)
-** Count: 94 patents
+** Count: 96 patents
-** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies simplified abstract (Vertex Pharmaceuticals Incorporated)]]
+** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)]]
-* [[:Category:CPC_C12N15/11|C12N15/11]] (DNA or RNA fragments; Modified forms thereof  (DNA or RNA not used in recombinant technology,)
+* [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available)
 ** Count: 46 patents
-** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]]
+** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]]
-* [[:Category:CPC_C12N15/907|C12N15/907]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media)
+* [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available)
-** Count: 33 patents
+** Count: 34 patents
-** Example: [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]]
+** Example: [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]]
-* [[:Category:CPC_C12N15/102|C12N15/102]] ({Mutagenizing nucleic acids})
+* [[:Category:CPC_C12N15/102|C12N15/102]] (No explanation available)
 ** Count: 27 patents
-** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies simplified abstract (Vertex Pharmaceuticals Incorporated)]]
+** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)]]
-* [[:Category:CPC_C12N2800/80|C12N2800/80]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media)
+* [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available)
 ** Count: 27 patents
-** Example: [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]]
+** Example: [[20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]]
-* [[:Category:CPC_C12N15/111|C12N15/111]] ({General methods applicable to biologically active non-coding nucleic acids})
+* [[:Category:CPC_C12N2800/80|C12N2800/80]] (No explanation available)
-** Count: 26 patents
+** Count: 27 patents
-** Example: [[20240229024. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]]
+** Example: [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]]
-* [[:Category:CPC_C12N15/113|C12N15/113]] (Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing  (when used in plants)
+* [[:Category:CPC_C12N15/113|C12N15/113]] (No explanation available)
+** Count: 18 patents
+** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)]]
+* [[:Category:CPC_C12N15/86|C12N15/86]] (No explanation available)
 ** Count: 17 patents
-** Example: [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies simplified abstract (Vertex Pharmaceuticals Incorporated)]]
+** Example: [[20240350666. COMPOSITIONS AND METHODS FOR HIGH EFFICIENCY GENOME EDITING (Children`s Medical Center Corporation)]]
-* [[:Category:CPC_C12N15/86|C12N15/86]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media)
+* [[:Category:CPC_C12N15/63|C12N15/63]] (No explanation available)
-** Count: 16 patents
-** Example: [[20240350666. COMPOSITIONS AND METHODS FOR HIGH EFFICIENCY GENOME EDITING simplified abstract (Children`s Medical Center Corporation)]]
-* [[:Category:CPC_C12N15/63|C12N15/63]] (Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression)
 ** Count: 14 patents
-** Example: [[20240124877. RNA CLEAVAGE-INDUCED TRANSCRIPT STABILIZER AND USES THEREOF simplified abstract (Massachusetts Institute of Technology)]]
+** Example: [[20240124877. RNA CLEAVAGE-INDUCED TRANSCRIPT STABILIZER AND USES THEREOF (Massachusetts Institute of Technology)]]
 == Top Companies in Synthetic Biology ==
@@ Line 44: / Line 44: @@
 * Number of Synthetic Biology patents: 9
 * Top CPC codes:
-** [[:Category:CPC_C12N9/1081|C12N9/1081]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 5 patents
+** [[:Category:CPC_C12N9/1081|C12N9/1081]] (No explanation available): 5 patents
-** [[:Category:CPC_C12P19/12|C12P19/12]] (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer): 5 patents
+** [[:Category:CPC_C12P19/12|C12P19/12]] (No explanation available): 5 patents
-** [[:Category:CPC_C12N9/1051|C12N9/1051]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 5 patents
+** [[:Category:CPC_C12N9/1051|C12N9/1051]] (No explanation available): 5 patents
 * Recent patents:
-** [[20240191270. FERMENTATIVE PRODUCTION simplified abstract (INBIOSE N.V.)]] (20240613)
+** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613)
-** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240314)
+** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:The General Hospital Corporation|The General Hospital Corporation]] ===
 * Number of Synthetic Biology patents: 7
 * Top CPC codes:
-** [[:Category:CPC_C07K16/18|C07K16/18]] (PEPTIDES  (peptides in foodstuffs): 2 patents
+** [[:Category:CPC_C07K16/18|C07K16/18]] (No explanation available): 2 patents
-** [[:Category:CPC_A61P25/28|A61P25/28]] (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS): 2 patents
+** [[:Category:CPC_A61P25/28|A61P25/28]] (No explanation available): 2 patents
-** [[:Category:CPC_C07K14/775|C07K14/775]] (PEPTIDES  (peptides in foodstuffs): 2 patents
+** [[:Category:CPC_C07K14/775|C07K14/775]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240240207. Increasing Specificity for RNA-Guided Genome Editing simplified abstract (The General Hospital Corporation)]] (20240718)
+** [[20240240207. Increasing Specificity for RNA-Guided Genome Editing (The General Hospital Corporation)]] (20240718)
-** [[20240066102. Genome editing approaches to treat Spinal Muscular Atrophy simplified abstract (The General Hospital Corporation)]] (20240229)
+** [[20240066102. Genome editing approaches to treat Spinal Muscular Atrophy (The General Hospital Corporation)]] (20240229)
-** [[20240218334. Biosensors in Human Gut Organoids simplified abstract (The General Hospital Corporation)]] (20240704)
+** [[20240218334. Biosensors in Human Gut Organoids (The General Hospital Corporation)]] (20240704)
 === [[:Category:Fate Therapeutics, Inc.|Fate Therapeutics, Inc.]] ===
 * Number of Synthetic Biology patents: 6
 * Top CPC codes:
-** [[:Category:CPC_A61K39/4631|A61K39/4631]] ({Cellular immunotherapy}): 5 patents
+** [[:Category:CPC_A61K39/4631|A61K39/4631]] (No explanation available): 5 patents
-** [[:Category:CPC_A61K39/4611|A61K39/4611]] ({Cellular immunotherapy}): 4 patents
+** [[:Category:CPC_A61K39/4611|A61K39/4611]] (No explanation available): 4 patents
-** [[:Category:CPC_A61P35/00|A61P35/00]] (Antineoplastic agents): 4 patents
+** [[:Category:CPC_A61P35/00|A61P35/00]] (No explanation available): 4 patents
 * Recent patents:
-** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES simplified abstract (Fate Therapeutics, Inc.)]] (20240919)
+** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.)]] (20240919)
-** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240425)
+** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240425)
-** [[20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS simplified abstract (Fate Therapeutics, Inc.)]] (20240201)
+** [[20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS (Fate Therapeutics, Inc.)]] (20240201)
 === [[:Category:PRIME MEDICINE, INC.|PRIME MEDICINE, INC.]] ===
 * Number of Synthetic Biology patents: 4
 * Top CPC codes:
-** [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 4 patents
+** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 4 patents
-** [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 2 patents
-** [[:Category:CPC_C12N15/11|C12N15/11]] (DNA or RNA fragments; Modified forms thereof  (DNA or RNA not used in recombinant technology,): 2 patents
+** [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240711)
+** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240711)
-** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS simplified abstract (PRIME MEDICINE, INC.)]] (20240912)
+** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.)]] (20240912)
-** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240523)
+** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240523)
 === [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]] ===
 * Number of Synthetic Biology patents: 4
 * Top CPC codes:
-** [[:Category:CPC_C12N15/111|C12N15/111]] ({General methods applicable to biologically active non-coding nucleic acids}): 4 patents
+** [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available): 4 patents
-** [[:Category:CPC_C12N15/907|C12N15/907]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N9/1276|C12N9/1276]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N9/1276|C12N9/1276]] (No explanation available): 3 patents
 * Recent patents:
-** [[20240117382. DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) simplified abstract (The Broad Institute, Inc.)]] (20240411)
+** [[20240117382. DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF CRISPR SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOIETIC STEM CELLS (HSCs) (The Broad Institute, Inc.)]] (20240411)
-** [[20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE simplified abstract (The Broad Institute, Inc.)]] (20240516)
+** [[20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE (The Broad Institute, Inc.)]] (20240516)
-** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20241003)
+** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003)
 === [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]] ===
 * Number of Synthetic Biology patents: 4
 * Top CPC codes:
-** [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 2 patents
-** [[:Category:CPC_C12N15/11|C12N15/11]] (DNA or RNA fragments; Modified forms thereof  (DNA or RNA not used in recombinant technology,): 2 patents
+** [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240301373. FANZORS ARE RNA-GUIDED NUCLEASES ENCODED IN EUKARYOTIC GENOMES simplified abstract (Massachusetts Institute of Technology)]] (20240912)
+** [[20240301373. FANZORS ARE RNA-GUIDED NUCLEASES ENCODED IN EUKARYOTIC GENOMES (Massachusetts Institute of Technology)]] (20240912)
-** [[20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL simplified abstract (Massachusetts Institute of Technology)]] (20240229)
+** [[20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL (Massachusetts Institute of Technology)]] (20240229)
-** [[20240035008. GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS simplified abstract (Massachusetts Institute of Technology)]] (20240201)
+** [[20240035008. GENOMIC EDITING WITH SITE-SPECIFIC RETROTRANSPOSONS (Massachusetts Institute of Technology)]] (20240201)
 === [[:Category:The Board of Trustees of the Leland Stanford Junior University|The Board of Trustees of the Leland Stanford Junior University]] ===
 * Number of Synthetic Biology patents: 4
 * Top CPC codes:
-** [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 4 patents
+** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 4 patents
-** [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N15/907|C12N15/907]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240263173. HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20240808)
+** [[20240263173. HIGH-THROUGHPUT PRECISION GENOME EDITING IN HUMAN CELLS (The Board of Trustees of the Leland Stanford Junior University)]] (20240808)
-** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
+** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
-** [[20240018493. KNOCK-IN OF LARGE DNA FOR LONG-TERM HIGH GENOMIC EXPRESSION simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20240118)
+** [[20240018493. KNOCK-IN OF LARGE DNA FOR LONG-TERM HIGH GENOMIC EXPRESSION (The Board of Trustees of the Leland Stanford Junior University)]] (20240118)
 === [[:Category:UNIVERSITY OF MASSACHUSETTS|UNIVERSITY OF MASSACHUSETTS]] ===
 * Number of Synthetic Biology patents: 4
 * Top CPC codes:
-** [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N15/907|C12N15/907]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240141359. GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY simplified abstract (UNIVERSITY OF MASSACHUSETTS)]] (20240502)
+** [[20240141359. GENOME EDITING FOR TREATING MUSCULAR DYSTROPHY (UNIVERSITY OF MASSACHUSETTS)]] (20240502)
-** [[20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING simplified abstract (UNIVERSITY OF MASSACHUSETTS)]] (20240523)
+** [[20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS)]] (20240523)
-** [[20240036027. Nanopore Biosensors and Uses Thereof simplified abstract (UNIVERSITY OF MASSACHUSETTS)]] (20240201)
+** [[20240036027. Nanopore Biosensors and Uses Thereof (UNIVERSITY OF MASSACHUSETTS)]] (20240201)
 === [[:Category:Wisconsin Alumni Research Foundation|Wisconsin Alumni Research Foundation]] ===
 * Number of Synthetic Biology patents: 3
 * Top CPC codes:
-** [[:Category:CPC_A61K35/17|A61K35/17]] (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES  (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms): 2 patents
+** [[:Category:CPC_A61K35/17|A61K35/17]] (No explanation available): 2 patents
-** [[:Category:CPC_A61K39/4611|A61K39/4611]] ({Cellular immunotherapy}): 2 patents
+** [[:Category:CPC_A61K39/4611|A61K39/4611]] (No explanation available): 2 patents
-** [[:Category:CPC_A61K39/4631|A61K39/4631]] ({Cellular immunotherapy}): 2 patents
+** [[:Category:CPC_A61K39/4631|A61K39/4631]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240711)
+** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240711)
-** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240425)
+** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240425)
-** [[20240026466. CELL-BASED DNA SENSORS AND METHODS OF USING SAME simplified abstract (Wisconsin Alumni Research Foundation)]] (20240125)
+** [[20240026466. CELL-BASED DNA SENSORS AND METHODS OF USING SAME (Wisconsin Alumni Research Foundation)]] (20240125)
 === [[:Category:Prime Medicine, Inc.|Prime Medicine, Inc.]] ===
 * Number of Synthetic Biology patents: 3
 * Top CPC codes:
-** [[:Category:CPC_C12N9/22|C12N9/22]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 3 patents
+** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 3 patents
-** [[:Category:CPC_C12N9/1276|C12N9/1276]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N9/1276|C12N9/1276]] (No explanation available): 2 patents
-** [[:Category:CPC_C12N2310/20|C12N2310/20]] (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA  (microbiological testing media): 2 patents
+** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 2 patents
 * Recent patents:
-** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY simplified abstract (Prime Medicine, Inc.)]] (20241024)
+** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.)]] (20241024)
-** [[20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA simplified abstract (Prime Medicine, Inc.)]] (20241114)
+** [[20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA (Prime Medicine, Inc.)]] (20241114)
-** [[20240360476. Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy simplified abstract (Prime Medicine, Inc.)]] (20241031)
+** [[20240360476. Genome Editing Compositions and Methods for Treatment of Myotonic Dystrophy (Prime Medicine, Inc.)]] (20241031)
 == New Companies in Synthetic Biology (Last Month) ==
@@ Line 150: / Line 150: @@
 [[File:Emerging_Technology_Areas_in_Synthetic_Biology.png|border|800px]]
-* [[:Category:CPC_G01N27/44704|G01N27/44704]] (using electrophoresis)
+* [[:Category:CPC_G01N27/44704|G01N27/44704]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240044837. BIOSENSOR simplified abstract (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
+** Example: [[20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
-* [[:Category:CPC_B03C5/005|B03C5/005]] ({Dielectrophoresis, i.e. dielectric particles migrating towards the region of highest field strength  ()
+* [[:Category:CPC_B03C5/005|B03C5/005]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240044837. BIOSENSOR simplified abstract (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
+** Example: [[20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
-* [[:Category:CPC_G01N27/44782|G01N27/44782]] (using electrophoresis)
+* [[:Category:CPC_G01N27/44782|G01N27/44782]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240044837. BIOSENSOR simplified abstract (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
+** Example: [[20240044837. BIOSENSOR (Taiwan Semiconductor Manufacturing Company, Ltd.)]]
-* [[:Category:CPC_A61P25/00|A61P25/00]] (Drugs for disorders of the nervous system)
+* [[:Category:CPC_A61P25/00|A61P25/00]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240043830. MULTIPLEX EPIGENOME EDITING simplified abstract (The Trustees of Columbia University in the City of New York)]]
+** Example: [[20240043830. MULTIPLEX EPIGENOME EDITING (The Trustees of Columbia University in the City of New York)]]
-* [[:Category:CPC_G16B50/30|G16B50/30]] (BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY)
+* [[:Category:CPC_G16B50/30|G16B50/30]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240320462. Biocomputing platform and Boolean logic gates simplified abstract (Regents of the University of Minnesota)]]
+** Example: [[20240320462. Biocomputing platform and Boolean logic gates (Regents of the University of Minnesota)]]
-* [[:Category:CPC_G06N3/002|G06N3/002]] ({Biomolecular computers, i.e. using biomolecules, proteins, cells  (using DNA)
+* [[:Category:CPC_G06N3/002|G06N3/002]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240320462. Biocomputing platform and Boolean logic gates simplified abstract (Regents of the University of Minnesota)]]
+** Example: [[20240320462. Biocomputing platform and Boolean logic gates (Regents of the University of Minnesota)]]
-* [[:Category:CPC_G01N33/02|G01N33/02]] (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES  (measuring or testing processes other than immunoassay, involving enzymes or microorganisms)
+* [[:Category:CPC_G01N33/02|G01N33/02]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD simplified abstract (The Regents of the University of California)]]
+** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)]]
-* [[:Category:CPC_G01N27/227|G01N27/227]] (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES  (measuring or testing processes other than immunoassay, involving enzymes or microorganisms)
+* [[:Category:CPC_G01N27/227|G01N27/227]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD simplified abstract (The Regents of the University of California)]]
+** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)]]
-* [[:Category:CPC_G01N27/221|G01N27/221]] (INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES  (measuring or testing processes other than immunoassay, involving enzymes or microorganisms)
+* [[:Category:CPC_G01N27/221|G01N27/221]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD simplified abstract (The Regents of the University of California)]]
+** Example: [[20240319126. MULTI-SCALE, NANO- TO MESOSTRUCTURAL ENGINEERING OF SILK BIOPOLYMER-INTERLAYER BIOSENSORS FOR CONTINUOUS CO-MONITORING OF NUTRIENTS IN FOOD (The Regents of the University of California)]]
-* [[:Category:CPC_C12Y303/01001|C12Y303/01001]] (ENZYMES)
+* [[:Category:CPC_C12Y303/01001|C12Y303/01001]] (No explanation available)
 ** Count: 1 patents
-** Example: [[20240318209. GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF simplified abstract (Beijing University of Chemical Technology)]]
+** Example: [[20240318209. GENETICALLY ENGINEERED BACTERIUM USING GLUCOSE AS SUBSTRATE FOR DE NOVO SYNTHESIS OF VANILLIN AND APPLICATION THEREOF (Beijing University of Chemical Technology)]]
 == Top Companies in Emerging Synthetic Biology Technologies ==
@@ Line 198: / Line 198: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 9 patents
 * Recent patents:
-** [[20240191270. FERMENTATIVE PRODUCTION simplified abstract (INBIOSE N.V.)]] (20240613)
+** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613)
-** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240314)
+** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:Bahram VALAMEHR|Bahram VALAMEHR of San Diego CA (US)]] ===
 * Number of Synthetic Biology patents: 6
@@ Line 206: / Line 206: @@
 ** [[:Category:Fate Therapeutics, Inc.|Fate Therapeutics, Inc.]]: 6 patents
 * Recent patents:
-** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES simplified abstract (Fate Therapeutics, Inc.)]] (20240919)
+** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.)]] (20240919)
-** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240425)
+** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240425)
-** [[20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS simplified abstract (Fate Therapeutics, Inc.)]] (20240201)
+** [[20240033355. ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS (Fate Therapeutics, Inc.)]] (20240201)
 === [[:Category:David R. Liu|David R. Liu of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 5
@@ Line 215: / Line 215: @@
 ** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 2 patents
 * Recent patents:
-** [[20240271116. SUPPRESSION OF PAIN BY GENE EDITING simplified abstract (President and Fellows of Harvard College)]] (20240815)
+** [[20240271116. SUPPRESSION OF PAIN BY GENE EDITING (President and Fellows of Harvard College)]] (20240815)
-** [[20240209329. PROGRAMMABLE CAS9-RECOMBINASE FUSION PROTEINS AND USES THEREOF simplified abstract (President and Fellows of Harvard College)]] (20240627)
+** [[20240209329. PROGRAMMABLE CAS9-RECOMBINASE FUSION PROTEINS AND USES THEREOF (President and Fellows of Harvard College)]] (20240627)
-** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20241003)
+** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003)
 === [[:Category:Pieter Coussement|Pieter Coussement]] ===
 * Number of Synthetic Biology patents: 5
@@ Line 223: / Line 223: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents
 * Recent patents:
-** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES simplified abstract (INBIOSE N.V.)]] (20241107)
+** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107)
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240191270. FERMENTATIVE PRODUCTION simplified abstract (INBIOSE N.V.)]] (20240613)
+** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613)
 === [[:Category:Thomas Decoene|Thomas Decoene]] ===
 * Number of Synthetic Biology patents: 5
@@ Line 231: / Line 231: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents
 * Recent patents:
-** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES simplified abstract (INBIOSE N.V.)]] (20241107)
+** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107)
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240191270. FERMENTATIVE PRODUCTION simplified abstract (INBIOSE N.V.)]] (20240613)
+** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613)
 === [[:Category:Annelies Vercauteren|Annelies Vercauteren]] ===
 * Number of Synthetic Biology patents: 5
@@ Line 239: / Line 239: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents
 * Recent patents:
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES simplified abstract (INBIOSE N.V.)]] (20240201)
+** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:Ryan BJORDAHL|Ryan BJORDAHL of San Diego CA (US)]] ===
 * Number of Synthetic Biology patents: 4
@@ Line 247: / Line 247: @@
 ** [[:Category:Fate Therapeutics, Inc.|Fate Therapeutics, Inc.]]: 4 patents
 * Recent patents:
-** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240411)
+** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240411)
-** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES simplified abstract (Fate Therapeutics, Inc.)]] (20240919)
+** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.)]] (20240919)
-** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240425)
+** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240425)
 === [[:Category:Jode GOODRIDGE|Jode GOODRIDGE of San Diego CA (US)]] ===
 * Number of Synthetic Biology patents: 4
@@ Line 255: / Line 255: @@
 ** [[:Category:Fate Therapeutics, Inc.|Fate Therapeutics, Inc.]]: 4 patents
 * Recent patents:
-** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240411)
+** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240411)
-** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES simplified abstract (Fate Therapeutics, Inc.)]] (20240919)
+** [[20240307540. PROTECTED EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES (Fate Therapeutics, Inc.)]] (20240919)
-** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240425)
+** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240425)
 === [[:Category:Kristof Vandewalle|Kristof Vandewalle]] ===
 * Number of Synthetic Biology patents: 4
@@ Line 263: / Line 263: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 4 patents
 * Recent patents:
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES simplified abstract (INBIOSE N.V.)]] (20240201)
+** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:Tom Tong LEE|Tom Tong LEE of San Diego CA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 271: / Line 271: @@
 ** [[:Category:Fate Therapeutics, Inc.|Fate Therapeutics, Inc.]]: 3 patents
 * Recent patents:
-** [[20240226293. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240711)
+** [[20240226293. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240711)
-** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240411)
+** [[20240115602. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240411)
-** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF simplified abstract (Fate Therapeutics, Inc.)]] (20240425)
+** [[20240131156. ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF (Fate Therapeutics, Inc.)]] (20240425)
 === [[:Category:Wei Hsi YEH|Wei Hsi YEH of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 280: / Line 280: @@
 ** [[:Category:Prime Medicine, Inc.|Prime Medicine, Inc.]]: 1 patents
 * Recent patents:
-** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240711)
+** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240711)
-** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY simplified abstract (Prime Medicine, Inc.)]] (20241024)
+** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.)]] (20241024)
-** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240523)
+** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240523)
 === [[:Category:Aaron Nakwon CHANG|Aaron Nakwon CHANG of Lexington MA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 288: / Line 288: @@
 ** [[:Category:PRIME MEDICINE, INC.|PRIME MEDICINE, INC.]]: 3 patents
 * Recent patents:
-** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240711)
+** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240711)
-** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS simplified abstract (PRIME MEDICINE, INC.)]] (20240912)
+** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.)]] (20240912)
-** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240523)
+** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240523)
 === [[:Category:Andrew Vito Anzalone|Andrew Vito Anzalone of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 296: / Line 296: @@
 ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 3 patents
 * Recent patents:
-** [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20240711)
+** [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20240711)
-** [[20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE simplified abstract (The Broad Institute, Inc.)]] (20240516)
+** [[20240158779. METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE (The Broad Institute, Inc.)]] (20240516)
-** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20241003)
+** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003)
 === [[:Category:Roman Lvovitch BOGORAD|Roman Lvovitch BOGORAD of South Boston MA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 305: / Line 305: @@
 ** [[:Category:CRISPR THERAPEUTICS AG|CRISPR THERAPEUTICS AG]]: 1 patents
 * Recent patents:
-** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A simplified abstract (CRISPR THERAPEUTICS AG)]] (20240711)
+** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG)]] (20240711)
-** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY simplified abstract (CRISPR Therapeutics AG)]] (20240530)
+** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG)]] (20240530)
-** [[20240167060. COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES simplified abstract (CRISPR Therapeutics AG)]] (20240523)
+** [[20240167060. COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES (CRISPR Therapeutics AG)]] (20240523)
 === [[:Category:Dewi HARJANTO|Dewi HARJANTO of Brookline MA (US)]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 314: / Line 314: @@
 ** [[:Category:PRIME MEDICINE, INC.|PRIME MEDICINE, INC.]]: 1 patents
 * Recent patents:
-** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY simplified abstract (Prime Medicine, Inc.)]] (20241024)
+** [[20240352453. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY (Prime Medicine, Inc.)]] (20241024)
-** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS simplified abstract (PRIME MEDICINE, INC.)]] (20240912)
+** [[20240301444. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS (PRIME MEDICINE, INC.)]] (20240912)
-** [[20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA simplified abstract (Prime Medicine, Inc.)]] (20241114)
+** [[20240376466. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FANCONI ANEMIA (Prime Medicine, Inc.)]] (20241114)
 === [[:Category:Sofie Aesaert|Sofie Aesaert]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 322: / Line 322: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 3 patents
 * Recent patents:
-** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES simplified abstract (INBIOSE N.V.)]] (20241107)
+** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107)
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:Gert Peters|Gert Peters]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 330: / Line 330: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 3 patents
 * Recent patents:
-** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES simplified abstract (INBIOSE N.V.)]] (20241107)
+** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107)
-** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL simplified abstract (INBIOSE N.V.)]] (20240627)
+** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627)
-** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES simplified abstract (INBIOSE N.V.)]] (20241003)
+** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003)
 === [[:Category:Jin-Soo Kim|Jin-Soo Kim]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 338: / Line 338: @@
 ** [[:Category:TOOLGEN INCORPORATED|TOOLGEN INCORPORATED]]: 3 patents
 * Recent patents:
-** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240215)
+** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240215)
-** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240718)
+** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240718)
-** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240125)
+** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240125)
 === [[:Category:Seung Woo Cho|Seung Woo Cho]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 346: / Line 346: @@
 ** [[:Category:TOOLGEN INCORPORATED|TOOLGEN INCORPORATED]]: 3 patents
 * Recent patents:
-** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240215)
+** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240215)
-** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240718)
+** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240718)
-** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240125)
+** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240125)
 === [[:Category:Sojung Kim|Sojung Kim]] ===
 * Number of Synthetic Biology patents: 3
@@ Line 354: / Line 354: @@
 ** [[:Category:TOOLGEN INCORPORATED|TOOLGEN INCORPORATED]]: 3 patents
 * Recent patents:
-** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240215)
+** [[20240052356. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240215)
-** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240718)
+** [[20240240192. Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240718)
-** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells simplified abstract (TOOLGEN INCORPORATED)]] (20240125)
+** [[20240026367. Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells (TOOLGEN INCORPORATED)]] (20240125)
 === [[:Category:Krishanu Saha|Krishanu Saha of Madison WI (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 362: / Line 362: @@
 ** [[:Category:Wisconsin Alumni Research Foundation|Wisconsin Alumni Research Foundation]]: 2 patents
 * Recent patents:
-** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240711)
+** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240711)
-** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240425)
+** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240425)
 === [[:Category:Lauren Sarko|Lauren Sarko of Middleton WI (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 369: / Line 369: @@
 ** [[:Category:Wisconsin Alumni Research Foundation|Wisconsin Alumni Research Foundation]]: 2 patents
 * Recent patents:
-** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240711)
+** [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240711)
-** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING simplified abstract (Wisconsin Alumni Research Foundation)]] (20240425)
+** [[20240131066. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] (20240425)
 === [[:Category:Ante Sven Lundberg|Ante Sven Lundberg of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 377: / Line 377: @@
 ** [[:Category:Vertex Phamaceuticals Incorporated|Vertex Phamaceuticals Incorporated]]: 1 patents
 * Recent patents:
-** [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies simplified abstract (Vertex Pharmaceuticals Incorporated)]] (20240711)
+** [[20240226339. Materials and Methods for Treatment of Hemoglobinopathies (Vertex Pharmaceuticals Incorporated)]] (20240711)
-** [[20240066150. MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS simplified abstract (Vertex Phamaceuticals Incorporated)]] (20240229)
+** [[20240066150. MATERIALS AND METHODS FOR TREATMENT OF PAIN RELATED DISORDERS (Vertex Phamaceuticals Incorporated)]] (20240229)
 === [[:Category:Chase Lawrence Beisel|Chase Lawrence Beisel of Raleigh NC (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 384: / Line 384: @@
 ** [[:Category:North Carolina State University|North Carolina State University]]: 2 patents
 * Recent patents:
-** [[20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY simplified abstract (North Carolina State University)]] (20240711)
+** [[20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University)]] (20240711)
-** [[20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY simplified abstract (North Carolina State University)]] (20240425)
+** [[20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University)]] (20240425)
 === [[:Category:Scott Patrick Collins|Scott Patrick Collins of Raleigh NC (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 391: / Line 391: @@
 ** [[:Category:North Carolina State University|North Carolina State University]]: 2 patents
 * Recent patents:
-** [[20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY simplified abstract (North Carolina State University)]] (20240711)
+** [[20240229012. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University)]] (20240711)
-** [[20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY simplified abstract (North Carolina State University)]] (20240425)
+** [[20240132873. SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY (North Carolina State University)]] (20240425)
 === [[:Category:David Baram|David Baram]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 398: / Line 398: @@
 ** [[:Category:EmendoBio Inc.|EmendoBio Inc.]]: 2 patents
 * Recent patents:
-** [[20240229024. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240711)
+** [[20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240711)
-** [[20240132884. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240425)
+** [[20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240425)
 === [[:Category:Lior Izhar|Lior Izhar]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 405: / Line 405: @@
 ** [[:Category:EmendoBio Inc.|EmendoBio Inc.]]: 2 patents
 * Recent patents:
-** [[20240229024. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240711)
+** [[20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240711)
-** [[20240132884. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240425)
+** [[20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240425)
 === [[:Category:Rafi Emmanuel|Rafi Emmanuel]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 412: / Line 412: @@
 ** [[:Category:EmendoBio Inc.|EmendoBio Inc.]]: 2 patents
 * Recent patents:
-** [[20240229024. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240711)
+** [[20240229024. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240711)
-** [[20240132884. COMPOSITIONS FOR GENOME EDITING simplified abstract (EmendoBio Inc.)]] (20240425)
+** [[20240132884. COMPOSITIONS FOR GENOME EDITING (EmendoBio Inc.)]] (20240425)
 === [[:Category:Jonathan M. LEVY|Jonathan M. LEVY of Brookline MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 419: / Line 419: @@
 ** [[:Category:PRIME MEDICINE, INC.|PRIME MEDICINE, INC.]]: 2 patents
 * Recent patents:
-** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240711)
+** [[20240229038. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240711)
-** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE simplified abstract (PRIME MEDICINE, INC.)]] (20240523)
+** [[20240167026. GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF WILSON'S DISEASE (PRIME MEDICINE, INC.)]] (20240523)
 === [[:Category:Yuan WANG|Yuan WANG]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 427: / Line 427: @@
 ** [[:Category:HUAZHONG AGRICULTURAL UNIVERSITY|HUAZHONG AGRICULTURAL UNIVERSITY]]: 1 patents
 * Recent patents:
-** [[20240229045. APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAME simplified abstract (BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES)]] (20240711)
+** [[20240229045. APTAMER FOR SPECIFICALLY RECOGNIZING SOLUBLE ST2 PROTEIN AND APPLICATION OF THE SAME (BEIJING INSTITUTE OF HEART, LUNG AND BLOOD VESSEL DISEASES)]] (20240711)
-** [[20240368675. PAM-LESS ENDONUCLEASE AND GENE EDITING SYSTEM MEDIATED BY PAM-LESS ENDONUCLEASE simplified abstract (HUAZHONG AGRICULTURAL UNIVERSITY)]] (20241107)
+** [[20240368675. PAM-LESS ENDONUCLEASE AND GENE EDITING SYSTEM MEDIATED BY PAM-LESS ENDONUCLEASE (HUAZHONG AGRICULTURAL UNIVERSITY)]] (20241107)
 === [[:Category:James William Nelson|James William Nelson of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 434: / Line 434: @@
 ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 2 patents
 * Recent patents:
-** [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20240711)
+** [[20240229077. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20240711)
-** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES simplified abstract (The Broad Institute, Inc.)]] (20241003)
+** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003)
 === [[:Category:Chad Albert COWAN|Chad Albert COWAN of South Boston MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 442: / Line 442: @@
 ** [[:Category:CRISPR Therapeutics AG|CRISPR Therapeutics AG]]: 1 patents
 * Recent patents:
-** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A simplified abstract (CRISPR THERAPEUTICS AG)]] (20240711)
+** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG)]] (20240711)
-** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY simplified abstract (CRISPR Therapeutics AG)]] (20240530)
+** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG)]] (20240530)
 === [[:Category:Ante Sven LUNDBERG|Ante Sven LUNDBERG of South Boston MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 450: / Line 450: @@
 ** [[:Category:CRISPR Therapeutics AG|CRISPR Therapeutics AG]]: 1 patents
 * Recent patents:
-** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A simplified abstract (CRISPR THERAPEUTICS AG)]] (20240711)
+** [[20240229078. MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1A (CRISPR THERAPEUTICS AG)]] (20240711)
-** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY simplified abstract (CRISPR Therapeutics AG)]] (20240530)
+** [[20240175014. MATERIALS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (CRISPR Therapeutics AG)]] (20240530)
 === [[:Category:Rasmus O. Bak|Rasmus O. Bak of Stanford CA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 457: / Line 457: @@
 ** [[:Category:The Board of Trustees of the Leland Stanford Junior University|The Board of Trustees of the Leland Stanford Junior University]]: 2 patents
 * Recent patents:
-** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
+** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
-** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
+** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
 === [[:Category:Ayal Hendel|Ayal Hendel of Stanford CA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 464: / Line 464: @@
 ** [[:Category:The Board of Trustees of the Leland Stanford Junior University|The Board of Trustees of the Leland Stanford Junior University]]: 2 patents
 * Recent patents:
-** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
+** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
-** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
+** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
 === [[:Category:Matthew H. Porteus|Matthew H. Porteus of Stanford CA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 471: / Line 471: @@
 ** [[:Category:The Board of Trustees of the Leland Stanford Junior University|The Board of Trustees of the Leland Stanford Junior University]]: 2 patents
 * Recent patents:
-** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
+** [[20240124895. NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS (The Board of Trustees of the Leland Stanford Junior University)]] (20240418)
-** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction simplified abstract (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
+** [[20240401034. Chemically Modified Guide RNAs for CRISPR/CAS-Mediated Gene Correction (The Board of Trustees of the Leland Stanford Junior University)]] (20241205)
 === [[:Category:Michael Andreas Kock|Michael Andreas Kock]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 478: / Line 478: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Michael Lee Nuccio|Michael Lee Nuccio of Salem NH (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 485: / Line 485: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Frédéric Van Ex|Frédéric Van Ex]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 492: / Line 492: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Alexandra Elata|Alexandra Elata of Arlington MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 499: / Line 499: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Daniel Rodriguez Leal|Daniel Rodriguez Leal of Raleigh NC (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 506: / Line 506: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Joshua L. Price|Joshua L. Price of Cambridge MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 513: / Line 513: @@
 ** [[:Category:INARI AGRICULTURE TECHNOLOGY, INC.|INARI AGRICULTURE TECHNOLOGY, INC.]]: 2 patents
 * Recent patents:
-** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
+** [[20240294937. GENOME EDITING OF TRANSGENIC CROP PLANTS WITH MODIFIED TRANSGENIC LOCI (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240905)
-** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING simplified abstract (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
+** [[20240011043. GENERATION OF PLANTS WITH IMPROVED TRANSGENIC LOCI BY GENOME EDITING (INARI AGRICULTURE TECHNOLOGY, INC.)]] (20240111)
 === [[:Category:Sofie De Maeseneire|Sofie De Maeseneire]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 520: / Line 520: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 2 patents
 * Recent patents:
-** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240905)
+** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240905)
-** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240314)
+** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314)
 === [[:Category:Yatti De Nijs|Yatti De Nijs]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 527: / Line 527: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 2 patents
 * Recent patents:
-** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240905)
+** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240905)
-** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240314)
+** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314)
 === [[:Category:Tom Delmulle|Tom Delmulle]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 534: / Line 534: @@
 ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 2 patents
 * Recent patents:
-** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240905)
+** [[20240294958. EXTRACELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240905)
-** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS simplified abstract (INBIOSE N.V.)]] (20240314)
+** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314)
 === [[:Category:Yakeel T. Quiroz|Yakeel T. Quiroz of Charlestown MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 541: / Line 541: @@
 ** [[:Category:The General Hospital Corporation|The General Hospital Corporation]]: 2 patents
 * Recent patents:
-** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240829)
+** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240829)
-** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240912)
+** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240912)
 === [[:Category:Joseph F. Arboleda-Velasquez|Joseph F. Arboleda-Velasquez of Newton MA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 548: / Line 548: @@
 ** [[:Category:The General Hospital Corporation|The General Hospital Corporation]]: 2 patents
 * Recent patents:
-** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240829)
+** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240829)
-** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240912)
+** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240912)
 === [[:Category:Eric Reiman|Eric Reiman of Phoenix AZ (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 555: / Line 555: @@
 ** [[:Category:The General Hospital Corporation|The General Hospital Corporation]]: 2 patents
 * Recent patents:
-** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240829)
+** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240829)
-** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240912)
+** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240912)
 === [[:Category:Francisco Lopera|Francisco Lopera]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 562: / Line 562: @@
 ** [[:Category:The General Hospital Corporation|The General Hospital Corporation]]: 2 patents
 * Recent patents:
-** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240829)
+** [[20240287165. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240829)
-** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF simplified abstract (The General Hospital Corporation)]] (20240912)
+** [[20240301044. APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF (The General Hospital Corporation)]] (20240912)
 === [[:Category:Radwanul Hasan SIDDIQUE|Radwanul Hasan SIDDIQUE of Monrovia CA (US)]] ===
 * Number of Synthetic Biology patents: 2
@@ Line 569: / Line 569: @@
 ** [[:Category:Samsung Electronics Co., Ltd.|Samsung Electronics Co., Ltd.]]: 2 patents
 * Recent patents:
-** [[20240350024. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS simplified abstract (Samsung Electronics Co., Ltd.)]] (20241024)
+** [[20240350024. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS (Samsung Electronics Co., Ltd.)]] (20241024)
-** [[20240065566. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS simplified abstract (Samsung Electronics Co., Ltd.)]] (20240229)
+** [[20240065566. POLARIZED PHOTOPLETHYSMOGRAPHY (PPG) BIOSENSORS, ARRAYS AND SYSTEMS (Samsung Electronics Co., Ltd.)]] (20240229)
 == Top Collaborations in Synthetic Biology ==

Difference between revisions of "Synthetic Biology Patent Application Trends 2024"

Latest revision as of 06:07, 17 December 2024

Contents

Synthetic Biology Patent Application Filing Activity

Synthetic Biology patent applications in 2024

Top Technology Areas in Synthetic Biology

Top CPC Codes

Top Companies in Synthetic Biology

New Companies in Synthetic Biology (Last Month)

Emerging Technology Areas in Synthetic Biology

Top Companies in Emerging Synthetic Biology Technologies

Top Inventors in Synthetic Biology

Top Collaborations in Synthetic Biology

Top US States for Synthetic Biology Inventors

Top Cities for Synthetic Biology Inventors

Navigation menu

Search